Systemic complement factors in aging, Alzheimer's disease and other dementias: a longitudinal study over 10 years
Xiaofeng Fu1, Huimin Cai1, Shuiyue Quan1
1Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing, 100053, China.
Insights
Alzheimer's disease (AD) involves specific changes in blood complement factors that appear before and during the disease. This immune signature distinguishes AD from other dementias and aging, offering potential early detection markers.
Area of Science:
- Immunology
- Neuroscience
- Gerontology
Background:
- Complement dysregulation is implicated in Alzheimer's disease (AD), but its early changes and differentiation from normal aging are unclear.
- Understanding these dynamics is crucial for AD pathogenesis insights and identifying predictive systemic factors.
Purpose of the Study:
- To investigate the temporal profile of complement alterations preceding AD onset.
- To distinguish AD-related complement changes from age-related immune variations.
- To identify potential systemic biomarkers for early AD detection.
Main Methods:
- Analyzed plasma levels of 14 complement factors in two cohorts: a 10-year longitudinal study of cognitively normal individuals (n=235) and a cross-sectional study (n=323) with AD and other dementia types.
- Assessed complement factor levels every 2 years in the longitudinal cohort and once in the cross-sectional cohort.
Main Results:
- Aging showed gradual changes in specific complement factors (e.g., decreased C4, Factor I; increased Factor D).
- These age-related changes were more pronounced in individuals who later developed AD, appearing in preclinical and clinical AD stages.
- The observed complement profile was specific to AD, differentiating it from other dementias and normal aging.
Conclusions:
- An AD-specific peripheral complement signature is associated with disease development, linking aging and AD.
- Complement factors represent critical immune mediators and potential systemic markers for early AD detection.
- These findings suggest complement factors could be therapeutic targets in preclinical AD.
Background:
Complement dysregulation is increasingly recognized in Alzheimer's disease (AD). However, the temporal profile of complement alterations preceding AD onset and their distinction from age-related immune changes remain poorly defined. Clarifying these dynamics could provide insights into AD pathogenesis and identify systemic factors that predict disease onset and progression.
Methods:
We conducted a study involving two cohorts: a longitudinal cohort (n = 235; all cognitively normal at baseline) and a cross-sectional cohort (n = 323; including 53 with AD, 54 with vascular dementia, 51 with Parkinson's disease dementia, 56 with behavioral variant frontotemporal dementia, and 52 with dementia with Lewy bodies). Plasma levels of 14 complement factors were assessed every 2 years over a 10-year follow-up period in the longitudinal cohort and once in the cross-sectional cohort.
Results:
In the longitudinal cohort, aging was accompanied by gradual reductions in C4, C4b, Factor I, and Properdin and by increases in Factor D. These changes were more pronounced in individuals who subsequently developed AD. Importantly, this pattern of complement alterations was detectable during the preclinical and clinical phases of AD but was not observed in other dementias. In the cross-sectional cohort, the same complement profile was specific to AD and distinguished it from other dementia subtypes.
Conclusions:
The results of this study indicate an AD-specific peripheral complement signature associated with disease development, highlighting complement factors as critical immune mediators that link aging and AD. This signature implicates complement factors as promising systemic markers for early detection and potential therapeutic targeting in preclinical AD.
More Related Videos
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Complement System
Cognitive Development During Adulthood
